{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:00:33Z","timestamp":1793858433175,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Health Popul Nutr"],"DOI":"10.1186\/s41043-025-00973-5","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T10:36:10Z","timestamp":1750242970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact"],"prefix":"10.1186","volume":"44","author":[{"given":"Zahra","family":"Sarkoohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Mahdi","family":"Bastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Khajuei Gharaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Iranmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Adinepour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhane","family":"Khajezade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faegheh","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Akhlaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Kadkhodamanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Pourghadamyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Aria","family":"Nejadghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"5","key":"973_CR1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction\u2013associated steatotic liver disease: update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212\u20139.","journal-title":"Hepatology"},{"issue":"1","key":"973_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"6","key":"973_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1262-3636(08)74597-X","volume":"34","author":"L Serfaty","year":"2008","unstructured":"Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008;34(6):634\u20137.","journal-title":"Diabetes Metab"},{"issue":"6","key":"973_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the L","year":"2016","unstructured":"European Association for the Study of the L. European association for the study of D, European association for the study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402.","journal-title":"J Hepatol"},{"issue":"1","key":"973_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"973_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/cells9041005","volume":"9","author":"VA Piazzolla","year":"2020","unstructured":"Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells. 2020;9(4):1005.","journal-title":"Cells"},{"issue":"19","key":"973_CR7","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.3390\/jcm12196216","volume":"12","author":"W Eskridge","year":"2023","unstructured":"Eskridge W, Cryer DR, Schattenberg JM, Gastaldelli A, Malhi H, Allen AM, et al. Metabolic Dysfunction-Associated steatotic liver disease and metabolic Dysfunction-Associated steatohepatitis: the patient and physician perspective. J Clin Med. 2023;12(19):6216.","journal-title":"J Clin Med"},{"issue":"1","key":"973_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Reviews Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"6","key":"973_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"973_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","volume":"13","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Paik JM, Henry L, Yang J, Fernandes G, Stepanova M, et al. The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the united States. J Clin Experimental Hepatol. 2023;13(3):454\u201367.","journal-title":"J Clin Experimental Hepatol"},{"issue":"2","key":"973_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2337\/dc19-1113","volume":"43","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Tampi RP, Racila A, Qiu Y, Burns L, Younossi I, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. Diabetes Care. 2020;43(2):283\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"973_CR12","first-page":"64","volume":"36","author":"LM Glass","year":"2019","unstructured":"Glass LM, Hunt CM, Fuchs M, Su GL. Comorbidities and nonalcoholic fatty liver disease: the chicken, the egg, or both? Fed Practitioner. 2019;36(2):64.","journal-title":"Fed Practitioner"},{"issue":"12","key":"973_CR13","doi-asserted-by":"publisher","first-page":"e240096","DOI":"10.57264\/cer-2024-0096","volume":"13","author":"Y Kim","year":"2024","unstructured":"Kim Y, Medicis J, Davis M, Nunag D, Gish R. Costs associated with nonalcoholic steatohepatitis disease progression in medicare patients: a retrospective cohort study. J Comp Eff Res. 2024;13(12):e240096.","journal-title":"J Comp Eff Res"},{"issue":"11","key":"973_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"973_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"1","key":"973_CR16","doi-asserted-by":"publisher","first-page":"102068","DOI":"10.1016\/j.clinre.2022.102068","volume":"47","author":"H Tian","year":"2023","unstructured":"Tian H, Zhang K, Hui Z, Ren F, Ma Y, Han F, et al. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019. Clin Res Hepatol Gastroenterol. 2023;47(1):102068.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"973_CR17","doi-asserted-by":"crossref","unstructured":"Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 2023;7(10).","DOI":"10.1097\/HC9.0000000000000251"},{"issue":"4","key":"973_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","volume":"75","author":"P Golabi","year":"2021","unstructured":"Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in asia, the middle East and North africa: data from global burden of disease 2009\u20132019. J Hepatol. 2021;75(4):795\u2013809.","journal-title":"J Hepatol"},{"issue":"12","key":"973_CR19","doi-asserted-by":"publisher","first-page":"e34809","DOI":"10.2196\/34809","volume":"8","author":"H Chen","year":"2022","unstructured":"Chen H, Zhan Y, Zhang J, Cheng S, Zhou Y, Chen L, et al. The global, regional, and National burden and trends of NAFLD in 204 countries and territories: an analysis from global burden of disease 2019. JMIR Public Health Surveill. 2022;8(12):e34809.","journal-title":"JMIR Public Health Surveill"},{"issue":"11","key":"973_CR20","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(19)30179-2","volume":"7","author":"F Azizi","year":"2019","unstructured":"Azizi F, Hadaegh F, Hosseinpanah F, Mirmiran P, Amouzegar A, Abdi H, et al. Metabolic health in the middle East and North Africa. Lancet Diabetes Endocrinol. 2019;7(11):866\u201379.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"973_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.14740\/gr913w","volume":"10","author":"MH Ahmed","year":"2017","unstructured":"Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA, et al. Non-Alcoholic fatty liver disease in Africa and middle east: an attempt to predict the present and future implications on the healthcare system. Gastroenterol Res. 2017;10(5):271\u20139.","journal-title":"Gastroenterol Res"},{"issue":"8","key":"973_CR22","doi-asserted-by":"publisher","first-page":"e102830","DOI":"10.1371\/journal.pone.0102830","volume":"9","author":"AA Alsheikh-Ali","year":"2014","unstructured":"Alsheikh-Ali AA, Omar MI, Raal FJ, Rashed W, Hamoui O, Kane A, et al. Cardiovascular risk factor burden in Africa and the middle east: the Africa middle East cardiovascular epidemiological (ACE) study. PLoS ONE. 2014;9(8):e102830.","journal-title":"PLoS ONE"},{"issue":"4","key":"973_CR23","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s12072-021-10182-x","volume":"15","author":"FM Sanai","year":"2021","unstructured":"Sanai FM, Al Khathlan A, Al Fadhli A, Jazzar AS, Hashim AM, Mansour E, et al. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi arabia, united Arab Emirates and Kuwait. Hepatol Int. 2021;15(4):912\u201321.","journal-title":"Hepatol Int"},{"issue":"1","key":"973_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Reviews Gastroenterol Hepatol. 2022;19(1):60\u201378.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"10440","key":"973_CR25","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"Collaborators GBDCoD","year":"2024","unstructured":"Collaborators GBDCoD. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2100\u201332.","journal-title":"Lancet"},{"issue":"10440","key":"973_CR26","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"GBDRF Collaborators","year":"2024","unstructured":"Collaborators GBDRF. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2162\u2013203.","journal-title":"Lancet"},{"key":"973_CR27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/apt.17833","volume":"59","author":"P Golabi","year":"2024","unstructured":"Golabi P, Owrangi S, Younossi ZM. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis-prevalence, clinical impact, economic implications and management strategies. Aliment Pharmacol Ther. 2024;59:S1\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"973_CR28","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling Nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904.","journal-title":"J Hepatol"},{"issue":"Suppl","key":"973_CR29","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2022","unstructured":"Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;29(Suppl):S32.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"973_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"SG Sepanlou","year":"2020","unstructured":"Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and National burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"973_CR31","doi-asserted-by":"publisher","first-page":"1347459","DOI":"10.3389\/fphys.2024.1347459","volume":"15","author":"M Lin","year":"2024","unstructured":"Lin M, Gao B, Peng M, Chen X, Xiao H, Shi M, et al. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study. Front Physiol. 2024;15:1347459.","journal-title":"Front Physiol"},{"issue":"1","key":"973_CR32","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1038\/s41598-025-89293-6","volume":"15","author":"GE Chung","year":"2025","unstructured":"Chung GE, Yu SJ, Yoo J-J, Cho Y, Lee K-n, Shin DW, et al. Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults. Sci Rep. 2025;15(1):5777.","journal-title":"Sci Rep"},{"key":"973_CR33","first-page":"1990","volume":"369","author":"T Vos","year":"2020","unstructured":"Vos T, Lim S, Abbafati C, Abbas K, Abbasi M, Abbasifard M, et al. GBD 2019 diseases and injuries collaborators. Global Burd of. 2020;369:1990\u20132019.","journal-title":"Global Burd of"},{"key":"973_CR34","doi-asserted-by":"crossref","unstructured":"Alenezi YM, Harris R, Morling J, Card T. Prevalence of non-alcoholic fatty liver disease (NAFLD) in Saudi Arabia: systematic review and meta-analysis. Cureus 2023;15(6).","DOI":"10.7759\/cureus.40308"},{"issue":"5","key":"973_CR35","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72(5):1605\u201316.","journal-title":"Hepatology"},{"issue":"4","key":"973_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Reviews Gastroenterol Hepatol. 2021;18(4):223\u201338.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"4","key":"973_CR37","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the Art and identification of research gaps. Hepatology. 2019;70(4):1457\u201369.","journal-title":"Hepatology"},{"issue":"5","key":"973_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/cld.1139","volume":"18","author":"M Balakrishnan","year":"2021","unstructured":"Balakrishnan M. Women have a lower risk of nonalcoholic fatty liver disease but higher risk of nonalcoholic fatty liver disease fibrosis than men: summary of the findings of a systematic review and Meta-analysis. Clin Liver Disease. 2021;18(5):251\u20134.","journal-title":"Clin Liver Disease"},{"issue":"12","key":"973_CR39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"973_CR40","first-page":"1033","volume":"22","author":"Y CHEN","year":"2019","unstructured":"CHEN Y, WANG X, HAO H, CHENG L, SHAO X, ZHANG Y, et al. Relationship between socioeconomic status and Non-alcoholic fatty liver disease in huaian\u2019s retirees. Chin Gen Pract. 2019;22(9):1033.","journal-title":"Chin Gen Pract"},{"issue":"10258","key":"973_CR41","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"G Collaborators","year":"2020","unstructured":"Collaborators G, \u00c4rnl\u00f6v J. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"key":"973_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-020-01326-3","volume":"19","author":"Y Zou","year":"2020","unstructured":"Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a Nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis. 2020;19:1\u201311.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"973_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"}],"container-title":["Journal of Health, Population and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-025-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41043-025-00973-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41043-025-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T12:02:35Z","timestamp":1750248155000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhpn.biomedcentral.com\/articles\/10.1186\/s41043-025-00973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1186\/s41043-025-00973-5","relation":{},"ISSN":["2072-1315"],"issn-type":[{"value":"2072-1315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}